{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:31:17Z","timestamp":1771489877493,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,23]]},"DOI":"10.7759\/cureus.95245","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T18:39:27Z","timestamp":1761244767000},"source":"Crossref","is-referenced-by-count":1,"title":["Amiodarone-Induced Pulmonary Toxicity With Severe Pulmonary Fibrosis Complicated by Stenotrophomonas maltophilia Pneumonia: A Fatal Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Sachin","family":"Sapkota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Neri Rosario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suchita","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azucena","family":"Del Real","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Theresa D.","family":"Opina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar JA","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL, et al.. 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024, 149:e1-156. 10.1161\/CIR.0000000000001193","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)03230-x","article-title":"Rhythm or rate control in atrial fibrillation\u2014pharmacological intervention in atrial fibrillation (PIAF): a randomised trial","volume":"356","author":"Hohnloser SH","year":"2000","unstructured":"Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation\u2014pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet. 2000, 356:1789-94. 10.1016\/s0140-6736(00)03230-x","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00297-3","article-title":"Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemicdilated cardiomyopathy and asymptomaticnonsustained ventricular tachycardia\u2014AMIOVIRT","volume":"41","author":"Strickberger SA","year":"2003","unstructured":"Strickberger SA, Hummel JD, Bartlett TG, et al.. Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemicdilated cardiomyopathy and asymptomaticnonsustained ventricular tachycardia\u2014AMIOVIRT. J Am Coll Cardiol. 2003, 41:1707-12. 10.1016\/S0735-1097(03)00297-3","journal-title":"J Am Coll Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104521","article-title":"The role of amiodarone in contemporary management of complex cardiac arrhythmias","volume":"151","author":"Mujovi\u0107 N","year":"2020","unstructured":"Mujovi\u0107 N, Dobrev D, Marinkovi\u0107 M, Russo V, Potpara TS. The role of amiodarone in contemporary management of complex cardiac arrhythmias. Pharmacol Res. 2020, 151:104521. 10.1016\/j.phrs.2019.104521","journal-title":"Pharmacol Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9149(96)00452-3","article-title":"Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent","volume":"78","author":"Singh BN","year":"1996","unstructured":"Singh BN. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am J Cardiol. 1996, 78:41-53. 10.1016\/s0002-9149(96)00452-3","journal-title":"Am J Cardiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1378\/chest.93.6.1242","article-title":"Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2)","volume":"93","author":"Martin WJ 2nd","year":"1988","unstructured":"Martin WJ 2nd, Rosenow EC 3rd. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). Chest. 1988, 93:1242-8. 10.1378\/chest.93.6.1242","journal-title":"Chest"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206094","article-title":"Amiodarone therapy: updated practical insights","volume":"13","author":"\u0218orodoc V","year":"2024","unstructured":"\u0218orodoc V, Indrei L, Dobroghii C, et al.. Amiodarone therapy: updated practical insights. J Clin Med. 2024, 13:10.3390\/jcm13206094","journal-title":"J Clin Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12123217","article-title":"Pulmonary fibrosis related to amiodarone\u2014is it a standard pathophysiological pattern? A case-based literature review","volume":"12","author":"Budin CE","year":"2022","unstructured":"Budin CE, Cocuz IG, Sab\u0103u AH, Niculescu R, Ianosi IR, Ioan V, Cotoi OS. Pulmonary fibrosis related to amiodarone\u2014is it a standard pathophysiological pattern? A case-based literature review. Diagnostics (Basel). 2022, 12:10.3390\/diagnostics12123217","journal-title":"Diagnostics (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2022.03.003","article-title":"The inflammasome NLR family pyrin domain-containing protein 3 (NLRP3) as a novel therapeutic target for idiopathic pulmonary fibrosis","volume":"192","author":"Colunga Biancatelli RM","year":"2022","unstructured":"Colunga Biancatelli RM, Solopov PA, Catravas JD. The inflammasome NLR family pyrin domain-containing protein 3 (NLRP3) as a novel therapeutic target for idiopathic pulmonary fibrosis. Am J Pathol. 2022, 192:837-46. 10.1016\/j.ajpath.2022.03.003","journal-title":"Am J Pathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ph17081004","article-title":"L-carnitine ameliorates amiodarone-mediated alveolar damage: oxidative stress parameters, inflammatory markers, histological and ultrastructural insights","volume":"17","author":"Dawood SA","year":"2024","unstructured":"Dawood SA, Asseri AA, Shati AA, Eid RA, El-Gamal B, Zaki MS. L-carnitine ameliorates amiodarone-mediated alveolar damage: oxidative stress parameters, inflammatory markers, histological and ultrastructural insights. Pharmaceuticals (Basel). 2024, 17:1004. 10.3390\/ph17081004","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.07.1057","article-title":"Amiodarone-induced pulmonary toxicity leading to acute respiratory distress syndrome","volume":"164","author":"Rodriguez-Rivera AA","year":"2023","unstructured":"Rodriguez-Rivera AA, Chavez Melendez DA, Sultan S, Goyal A, Sharma B. Amiodarone-induced pulmonary toxicity leading to acute respiratory distress syndrome. Chest. 2023, 164:A1541-2. 10.1016\/j.chest.2023.07.1057","journal-title":"Chest"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2012.06.08","article-title":"Severe amiodarone induced pulmonary toxicity","volume":"4","author":"Nacca N","year":"2012","unstructured":"Nacca N, Bhamidipati CM, Yuhico LS, Pinnamaneni S, Szombathy T. Severe amiodarone induced pulmonary toxicity. J Thorac Dis. 2012, 4:667-70. 10.3978\/j.issn.2072-1439.2012.06.08","journal-title":"J Thorac Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/282540","article-title":"Amiodarone pulmonary toxicity","volume":"16","author":"Wolkove N","year":"2009","unstructured":"Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009, 16:43-8. 10.1155\/2009\/282540","journal-title":"Can Respir J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115564","article-title":"Combatting resistance: understanding multi-drug resistant pathogens in intensive care units","volume":"167","author":"Teng J","year":"2023","unstructured":"Teng J, Imani S, Zhou A, et al.. Combatting resistance: understanding multi-drug resistant pathogens in intensive care units. Biomed Pharmacother. 2023, 167:115564. 10.1016\/j.biopha.2023.115564","journal-title":"Biomed Pharmacother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1035812","article-title":"Risk factors of lower respiratory tract infection caused by Stenotrophomonas maltophilia: systematic review and meta-analysis","volume":"10","author":"Wang Y","year":"2022","unstructured":"Wang Y, Wang Y, Rong H, Guo Z, Xu J, Huang X. Risk factors of lower respiratory tract infection caused by Stenotrophomonas maltophilia: systematic review and meta-analysis. Front Public Health. 2022, 10:1035812. 10.3389\/fpubh.2022.1035812","journal-title":"Front Public Health"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.98.23.2574","article-title":"Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT)","volume":"98","author":"Deedwania PC","year":"1998","unstructured":"Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation. 1998, 98:2574-9. 10.1161\/01.cir.98.23.2574","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-022-01926-y","article-title":"A multicenter retrospective cohort study on predicting the risk for amiodarone pulmonary toxicity","volume":"22","author":"Kwok WC","year":"2022","unstructured":"Kwok WC, Ma TF, Chan JW, Pang HH, Ho JC. A multicenter retrospective cohort study on predicting the risk for amiodarone pulmonary toxicity. BMC Pulm Med. 2022, 22:128. 10.1186\/s12890-022-01926-y","journal-title":"BMC Pulm Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp100","article-title":"Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials","volume":"30","author":"Piccini JP","year":"2009","unstructured":"Piccini JP, Berger JS, O'Connor CM. Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials. Eur Heart J. 2009, 30:1245-53. 10.1093\/eurheartj\/ehp100","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2007.07.020","article-title":"A practical guide for clinicians who treat patients with amiodarone: 2007","volume":"4","author":"Goldschlager N","year":"2007","unstructured":"Goldschlager N, Epstein AE, Naccarelli GV, Olshansky B, Singh B, Collard HR, Murphy E. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007, 4:1250-9. 10.1016\/j.hrthm.2007.07.020","journal-title":"Heart Rhythm"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2438742","article-title":"Pulmonary adverse events associated with amiodarone: a real-world pharmacovigilance study based on the FDA adverse event reporting system","author":"Yang J","year":"2024","unstructured":"Yang J, Zhang G, You M, et al.. Pulmonary adverse events associated with amiodarone: a real-world pharmacovigilance study based on the FDA adverse event reporting system. Expert Opin Drug Saf. 2024, 1-11. 10.1080\/14740338.2024.2438742","journal-title":"Expert Opin Drug Saf"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-010-0181-3","article-title":"Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect?","volume":"99","author":"Schwaiblmair M","year":"2010","unstructured":"Schwaiblmair M, Berghaus T, Haeckel T, Wagner T, von Scheidt W. Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect?. Clin Res Cardiol. 2010, 99:693-700. 10.1007\/s00392-010-0181-3","journal-title":"Clin Res Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.21608\/mjfmct.2020.19954.1006","article-title":"Oxidative stress in amiodarone-induced pulmonary toxicity in rats and the protective effect of L-carnitine and vitamin C","volume":"28","author":"Ahmed D","year":"2020","unstructured":"Ahmed D, Youssef MY, Emam NM. Oxidative stress in amiodarone-induced pulmonary toxicity in rats and the protective effect of L-carnitine and vitamin C. Mansoura J Forensic Med Clin Toxicol. 2020, 28:43-53. 10.21608\/mjfmct.2020.19954.1006","journal-title":"Mansoura J Forensic Med Clin Toxicol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2165\/11532320-000000000-00000","article-title":"Amiodarone: review of pulmonary effects and toxicity","volume":"33","author":"Papiris SA","year":"2010","unstructured":"Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, Manali ED. Amiodarone: review of pulmonary effects and toxicity. Drug Saf. 2010, 33:539-58. 10.2165\/11532320-000000000-00000","journal-title":"Drug Saf"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2008.152652","article-title":"Amiodarone: an effective antiarrhythmic drug with unusual side effects","volume":"96","author":"van Erven L","year":"2010","unstructured":"van Erven L, Schalij MJ. Amiodarone: an effective antiarrhythmic drug with unusual side effects. Heart. 2010, 96:1593-600. 10.1136\/hrt.2008.152652","journal-title":"Heart"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/s1092-9134(97)80008-1","article-title":"Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry","volume":"1","author":"Bedrossian CW","year":"1997","unstructured":"Bedrossian CW, Warren CJ, Ohar J, Bhan R. Amiodarone pulmonary toxicity: cytopathology, ultrastructure, and immunocytochemistry. Ann Diagn Pathol. 1997, 1:47-56. 10.1016\/s1092-9134(97)80008-1","journal-title":"Ann Diagn Pathol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.qjmed.a067973","article-title":"Amiodarone pulmonary toxicity: clinical and subclinical features","volume":"59","author":"Adams PC","year":"1986","unstructured":"Adams PC, Gibson GJ, Morley AR, Wright AJ, Corris PA, Reid DS, Campbell RW. Amiodarone pulmonary toxicity: clinical and subclinical features. Q J Med. 1986, 59:449-71. 10.1093\/oxfordjournals.qjmed.a067973","journal-title":"Q J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-199203000-00012","article-title":"Amiodarone pulmonary toxicity","volume":"303","author":"Pitcher WD","year":"1992","unstructured":"Pitcher WD. Amiodarone pulmonary toxicity. Am J Med Sci. 1992, 303:206-12. 10.1097\/00000441-199203000-00012","journal-title":"Am J Med Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.08.039","article-title":"Practical management guide for clinicians who treat patients with amiodarone","volume":"129","author":"Epstein AE","year":"2016","unstructured":"Epstein AE, Olshansky B, Naccarelli GV, Kennedy JI Jr, Murphy EJ, Goldschlager N. Practical management guide for clinicians who treat patients with amiodarone. Am J Med. 2016, 129:468-75. 10.1016\/j.amjmed.2015.08.039","journal-title":"Am J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.882757","article-title":"Amiodarone induced pulmonary toxicity: an unusual response to steroids","volume":"13","author":"Garg J","year":"2012","unstructured":"Garg J, Agrawal N, Marballi A, Agrawal S, Rawat N, Sule S, Lehrman SG. Amiodarone induced pulmonary toxicity: an unusual response to steroids. Am J Case Rep. 2012, 13:62-5. 10.12659\/AJCR.882757","journal-title":"Am J Case Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0b013e328334a3f4","article-title":"Amiodarone-induced pulmonary toxicity mimicking acute pulmonary edema","volume":"12","author":"Fabiani I","year":"2011","unstructured":"Fabiani I, Tacconi D, Grotti S, Brandini R, Salvadori C, Caremani M, Bolognese L. Amiodarone-induced pulmonary toxicity mimicking acute pulmonary edema. J Cardiovasc Med (Hagerstown). 2011, 12:361-5. 10.2459\/JCM.0b013e328334a3f4","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/927438","article-title":"Acute amiodarone pulmonary toxicity after drug holiday: a case report and review of the literature","volume":"2015","author":"Abuzaid A","year":"2015","unstructured":"Abuzaid A, Saad M, Ayan M, Kabach A, Haddad TM, Smer A, Arouni A. Acute amiodarone pulmonary toxicity after drug holiday: a case report and review of the literature. Case Rep Cardiol. 2015, 2015:927438. 10.1155\/2015\/927438","journal-title":"Case Rep Cardiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.41.709","article-title":"SP-D as a marker of amiodarone-induced pulmonary toxicity","volume":"41","author":"Umetani K","year":"2002","unstructured":"Umetani K, Abe M, Kawabata K, Iida T, Kohno I, Sawanobori T, Kugiyama K. SP-D as a marker of amiodarone-induced pulmonary toxicity. Intern Med. 2002, 41:709-12. 10.2169\/internalmedicine.41.709","journal-title":"Intern Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ppedcard.2018.08.001","article-title":"Amiodarone toxicity in two post-operative congenital heart disease patients","volume":"52","author":"Covi S","year":"2019","unstructured":"Covi S, Clark J, Delius R, Chauhan M. Amiodarone toxicity in two post-operative congenital heart disease patients. Prog Pedia Cardiol. 2019, 52:46-9. 10.1016\/j.ppedcard.2018.08.001","journal-title":"Prog Pedia Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.2147\/IMCRJ.S433740","article-title":"Too little, too late: a case of a swift fatal culmination of amiodarone induced pulmonary toxicity in an adult male","volume":"16","author":"Tan C","year":"2023","unstructured":"Tan C, Kumar P. Too little, too late: a case of a swift fatal culmination of amiodarone induced pulmonary toxicity in an adult male. Int Med Case Rep J. 2023, 16:679-87. 10.2147\/IMCRJ.S433740","journal-title":"Int Med Case Rep J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma PD","year":"2024","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis. 2024, 10.1093\/cid\/ciae403","journal-title":"Clin Infect Dis"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2024.2324365","article-title":"Risk factors for mortality in Stenotrophomonas maltophilia bacteremia - a meta-analysis","volume":"56","author":"Huang C","year":"2024","unstructured":"Huang C, Lin L, Kuo S. Risk factors for mortality in Stenotrophomonas maltophilia bacteremia - a meta-analysis. Infect Dis (Lond). 2024, 56:335-47. 10.1080\/23744235.2024.2324365","journal-title":"Infect Dis (Lond)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1186\/cc5063","article-title":"Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome","volume":"10","author":"Nseir S","year":"2006","unstructured":"Nseir S, Di Pompeo C, Brisson H, et al.. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome. Crit Care. 2006, 10:R143. 10.1186\/cc5063","journal-title":"Crit Care"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2022.10.025","article-title":"Treatment, clinical outcomes, and predictors of mortality among a national cohort of hospitalized patients with Stenotrophomonas maltophilia infection","volume":"214","author":"Appaneal HJ","year":"2023","unstructured":"Appaneal HJ, Lopes VV, LaPlante KL, Caffrey AR. Treatment, clinical outcomes, and predictors of mortality among a national cohort of hospitalized patients with Stenotrophomonas maltophilia infection. Public Health. 2023, 214:73-80. 10.1016\/j.puhe.2022.10.025","journal-title":"Public Health"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2649-5","article-title":"Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study","volume":"23","author":"Guerci P","year":"2019","unstructured":"Guerci P, Bellut H, Mokhtari M, et al.. Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study. Crit Care. 2019, 23:371. 10.1186\/s13054-019-2649-5","journal-title":"Crit Care"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60010162","article-title":"Hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in patients with hematologic malignancies\u2014a systematic review and meta-analysis","volume":"60","author":"Huang C","year":"2024","unstructured":"Huang C, Kuo S, Lin L. Hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in patients with hematologic malignancies\u2014a systematic review and meta-analysis. Medicina (Kaunas). 2024, 60:162. 10.3390\/medicina60010162","journal-title":"Medicina (Kaunas)"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-023-01144-7","article-title":"Assessment of the relative benefits of monotherapy and combination therapy approaches to the treatment of hospital-acquired Stenotrophomonas maltophilia pneumonia: a multicenter, observational, real-world study","volume":"13","author":"Chen L","year":"2023","unstructured":"Chen L, Hua J, Hong S, et al.. Assessment of the relative benefits of monotherapy and combination therapy approaches to the treatment of hospital-acquired Stenotrophomonas maltophilia pneumonia: a multicenter, observational, real-world study. Ann Intensive Care. 2023, 13:47. 10.1186\/s13613-023-01144-7","journal-title":"Ann Intensive Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/419402-amiodarone-induced-pulmonary-toxicity-with-severe-pulmonary-fibrosis-complicated-by-stenotrophomonas-maltophilia-pneumonia-a-fatal-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T18:39:29Z","timestamp":1761244769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/419402-amiodarone-induced-pulmonary-toxicity-with-severe-pulmonary-fibrosis-complicated-by-stenotrophomonas-maltophilia-pneumonia-a-fatal-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.95245","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}